Radionuklidbehandling af neuroendokrine tumorer
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Radionuklidbehandling af neuroendokrine tumorer. / Mortensen, Jann; Oturai, Peter; Højgaard, Liselotte; Knigge, Ulrich; Hansen, Carsten Palnaes; Martiný, Lars; Rasmussen, Palle; Kjær, Andreas; Oturai, Peter Sandor.
I: Ugeskrift for Laeger, Bind 172, Nr. 43, 25.10.2010, s. 2950-3.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Radionuklidbehandling af neuroendokrine tumorer
AU - Mortensen, Jann
AU - Oturai, Peter
AU - Højgaard, Liselotte
AU - Knigge, Ulrich
AU - Hansen, Carsten Palnaes
AU - Martiný, Lars
AU - Rasmussen, Palle
AU - Kjær, Andreas
AU - Oturai, Peter Sandor
PY - 2010/10/25
Y1 - 2010/10/25
N2 - Peptide receptor radionuclide therapy using somatostatin analogues labelled with beta-emitting isotopes can be given to patients with metastasized or inoperable neuroendocrine tumours provided these have increased uptake on octreotide scintigraphy. This is a brief review of the treatment principle, indications and contraindications and practices with (177)Lu-DOTATATE treatment used at Rigshospitalet. Side effects are generally mild and reversible. Severe long-term side effects are rare. The majority of patients will experience increased quality of life and partial tumour reduction or stabilization for a period of time. However, up to 20% will experience no treatment effect.
AB - Peptide receptor radionuclide therapy using somatostatin analogues labelled with beta-emitting isotopes can be given to patients with metastasized or inoperable neuroendocrine tumours provided these have increased uptake on octreotide scintigraphy. This is a brief review of the treatment principle, indications and contraindications and practices with (177)Lu-DOTATATE treatment used at Rigshospitalet. Side effects are generally mild and reversible. Severe long-term side effects are rare. The majority of patients will experience increased quality of life and partial tumour reduction or stabilization for a period of time. However, up to 20% will experience no treatment effect.
M3 - Tidsskriftartikel
VL - 172
SP - 2950
EP - 2953
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 43
ER -
ID: 34045116